@article {2046,
	title = {An intravitreal implant injection method for sustained drug delivery into mouse eyes.},
	journal = {Cell Rep Methods},
	volume = {1},
	year = {2021},
	month = {2021 Dec 20},
	abstract = {<p>Using small molecule drugs to treat eye diseases carries benefits of specificity, scalability, and transportability, but their efficacy is significantly limited by a fast intraocular clearance rate. Ocular drug implants (ODIs) present a compelling means for the slow and sustained release of small molecule drugs inside the eye. However, methods are needed to inject small molecule ODIs into animals with small eyes, such as mice, which are the primary genetic models for most human ocular diseases. Consequently, it has not been possible to fully investigate efficacy and ocular pharmacokinetics of ODIs. Here, we present a robust, cost-effective, and minimally invasive method called \&quot;mouse implant intravitreal injection\&quot; (MI3) to deliver ODIs into mouse eyes. This method will expand ODI research to cover the breadth of human eye diseases modeled in mice.</p>
},
	issn = {2667-2375},
	doi = {10.1016/j.crmeth.2021.100125},
	author = {Sun, Young Joo and Lin, Cheng-Hui and Wu, Man-Ru and Lee, Soo Hyeon and Yang, Jing and Kunchur, Caitlin R and Mujica, Elena M and Chiang, Bryce and Jung, Youn Soo and Wang, Sui and Mahajan, Vinit B}
}
